Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.

Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...

With more cytokine-based drugs entering clinical trials and novel combination and masking technologies being used, there is a growing need for experts to discuss, understand, and build on the ...

These pro-inflammatory cytokines not only drive the autoimmune process but also create an environment conducive to chronic inflammation. Conversely, in the context of cancer, the cytokine milieu ...

Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Highlighted potential long-term benefits of INB-200. As of October 18, 2024, five patients remained alive, three patients had ...

COVID and the 1918 flu pandemic gave us playbooks on how to prepare for the next pandemic. But we aren’t using it.

Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.